Climb Bio Shares Rise on Positive Trial Data for Kidney Disease Drug
Climb Bio (CLYM) saw its stock rise more than 13% in premarket trading after reporting initial data from a Phase 1 trial of CLYM116, an anti-APRIL monoclonal antibody targeting IgA nephropathy. The drug is being developed to treat this chronic kidney disease. The positive early results suggest potential for the therapy's efficacy and safety profile in patients with IgA nephropathy. This marks a significant milestone as Climb Bio continues its clinical development program, which could lead to further trials or regulatory discussions if these findings are validated in larger studies.
Tickers: $CLYM